<DOC>
	<DOCNO>NCT02240550</DOCNO>
	<brief_summary>This investigation double-armed , randomize ( Blinded patient Blinded examiner ) prospective study design collect perioperative postoperative data compare QOL ProFlor vs. Lichtenstein inguinal hernia repair .</brief_summary>
	<brief_title>A Comparative Clinical Study Evaluate Effectiveness ProFlor vs. Lichtenstein Inguinal Hernia Repair</brief_title>
	<detailed_description>The primary objective study evaluate immediate short-term amount post-operative pain , quality life ( QOL ) , well return normal activity ( work ) two procedure . Carolinas Comfort Scale ( CCS ) Visual Analogue Score ( VAS ) assessment hold regular interval evaluate objective . The secondary objective study identify short-term study related complications/adverse event . The follow immediately post-operative , post-operative day 1 , 1 , 2 , 4 week . The first 4th week 's visit mandatory office visit ( possible ) . If available office visit , CCS assessment mail conduct via phone . Up 50 patient may enrol study ( 25 per arm ) . A report may generate presentation international meeting AHS , EHS , APHS decide lead investigator .</detailed_description>
	<mesh_term>Hernia</mesh_term>
	<mesh_term>Hernia , Inguinal</mesh_term>
	<criteria>Scheduled undergo routine inguinal hernia repair Male Female patient 18 65 year old Competent give consent Clinically relevant inguinal hernia ( classification : EHS P L/M 1/2/3 ) Defect size operation 5mm 35mm Diagnosed unilateral , direct , indirect mixed inguinal hernia Primary hernia operative site Signs obvious local systemic infection Any previous surgery hernia operative site Hernia inguinal area Hernia identify indirect direct Femoral hernia Known collagen disorder Presenting unstable angina NYHA class IV Known Pregnancy Nursing woman Active drug user Recurrence repair method Patients giant inguinoscrotal hernia abdominal wall defect &gt; 35 mm diameter e.g . large direct combine inguinal hernia type Nyhus IIIb / EHS P L/M 1/2/3 Immunosuppression , prednisone &gt; 15 mg/day , active chemotherapy End stage renal disease Abdominal ascites Skin infection area surgical field BMI &gt; 35 Peritoneum close Patient clinically relevant comorbidity ( antithrombic prophylaxis due cardiovascular pathology , diabetes require insulin therapy immunodeficiency syndrome type ) Neutropenia absolute neutrophil count ( ANC ) &lt; 500 cells/mm3 Significant lifethreatening condition ( e.g. , endocarditis ) would confound interfere procedure Patients require anticoagulant monitoring activate partial thromboplastin time ( aPTT ) Patients unwilling forego blood and/or blood product donation least 3 month initiation first study device Treatment investigational medicinal product within 30 day enrollment duration study Investigational device present , remove within 30 day enrollment , presence devicerelated infection Patients investigator considers unlikely adhere protocol complete clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Open Inguinal Hernia</keyword>
</DOC>